|Bid||0.000 x 0|
|Ask||0.000 x 0|
|Day's Range||0.0000 - 0.0000|
|52 Week Range|
|Beta (3Y Monthly)||-0.37|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
DiaMedica Therapeutics Inc. (“DiaMedica”) (DMAC) (TSX‑V:DMA), a clinical stage biopharmaceutical company, announced today the pricing of its initial public offering in the United States of 4,100,000 of its common shares at a price to the public of $4.00 per share. All of the common shares are being offered by DiaMedica. The common shares are expected to begin trading December 7, 2018 on The Nasdaq Capital Market under the symbol “DMAC.” The offering is expected to close on December 11, 2018, subject to the satisfaction of customary closing conditions.
DiaMedica Therapeutics Inc. (TSX Venture:DMA) (DMCAF), a clinical stage biopharmaceutical company, announced today that it has applied to list its common shares on The Nasdaq Capital Market. In connection with the planned U.S. listing, the Company, as authorized by its shareholders on November 6, 2018, is implementing a consolidation of its outstanding common shares. “We have made significant progress in positioning DM199 to treat patients with stroke and kidney diseases, including having recently announced a partnership with Ahon Pharmaceuticals, a subsidiary of Fosun Pharmaceuticals, for the treatment of acute ischemic stroke in China in an effort to deliver value to our shareholders,” said Rick Pauls, DiaMedica’s President and Chief Executive Officer. “This year, we have initiated a Phase II clinical study in patients who have suffered from an acute ischemic stroke and we are about to initiate a clinical study in patients with chronic kidney disease.
MINNEAPOLIS, Nov. 06, 2018 -- DiaMedica Therapeutics Inc. (TSX-V:DMA) (OTCQB:DMCAF), a clinical stage biopharmaceutical company, today announced the voting results from its.
Ahon Pharmaceutical Co Ltd.(Ahon Pharma), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co. Ltd, (Fosun Pharma, HKG: 02196 and SHA: 600196) and DiaMedica Therapeutics Inc. (TSX Venture: DMA and OTCQB: DMCAF) today entered into a license and collaboration agreement, which allows Ahon to have exclusive rights to develop and commercialize DM199 for acute ischemic stroke in mainland China, Taiwan, Hong Kong S.A.R. and Macau S.A.R. Fosun Pharma is one of China’s largest pharmaceutical firms with annual sales of more than USD$2 billion and an extensive related hospital sales force.
On May 21, 2018, Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH, 2607.HK) announced that the Company entered into a Share Purchase Agreement with Takeda Pharma AG. Pursuant to the agreement, Shanghai Pharma, through its Hong Kong subsidiary Shanghai Pharmaceuticals (HK), will acquire 100% equity interest of a wholly-owned subsidiary of Takeda AG with a consideration of US$144 million, resulting in its indirect acquisition of 26.34% shares of Techpool Bio-pharma Co., Ltd. (Techpool). Upon completion of the Proposed Acquisition, the shareholding in Techpool by Shanghai Pharma will be increased from 40.80% to 67.14% and Shanghai Pharma would achieve absolute control of Techpool.
MINNEAPOLIS, MN / ACCESSWIRE / April 3, 2018 / DiaMedica Therapeutics Inc. (''DiaMedica'') (TSX-V: DMA) (OTCQB: DMCAF), today announced that Mr. Rick Pauls, President and CEO, will present at The MicroCap ...
On Dec. 13, 2017, DiaMedica (TSX:DMA.V) announced a non-brokered private placement. Per the news release, each unit included one common share and one-half of one common share purchase warrant. This share offering was offered on a non-brokered private placement basis to accredited investors.